triazolam tablets, USP CIV
HALCION Tablets contain triazolam, a triazolobenzodiazepine hypnotic agent. Triazolam is a white crystalline powder, soluble in alcohol and poorly soluble in water.
HALCION is indicated for the short-term treatment of insomnia (generally 7–10 days). Use for more than 2–3 weeks requires complete reevaluation of the patient (see WARNINGS).
Prescriptions for HALCION should be written for short-term use (7–10 days) and it should not be prescribed in quantities exceeding a 1-month supply.
Media Articles Related to Halcion (Triazolam)
Source: MedicineNet Biorhythms Specialty [2015.11.23]
Category: Diseases and Conditions
Created: 6/6/2005 12:00:00 AM
Last Editorial Review: 11/23/2015 12:00:00 AM
Insomnia Treatment (Sleep Aids and Stimulants)
Source: MedicineNet Jet Lag Specialty [2015.11.20]
Title: Insomnia Treatment (Sleep Aids and Stimulants)
Category: Diseases and Conditions
Created: 9/24/1999 12:00:00 AM
Last Editorial Review: 11/20/2015 12:00:00 AM
Insomnia Pictures Slideshow: 10 Tips to Avoid Insomnia
Source: MedicineNet Sleep Aids And Stimulants Specialty [2015.09.08]
Title: Insomnia Pictures Slideshow: 10 Tips to Avoid Insomnia
Created: 12/10/2008 12:00:00 AM
Last Editorial Review: 9/8/2015 12:00:00 AM
Published Studies Related to Halcion (Triazolam)
Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women. [2011.06]
RATIONALE: Gender plays a critical role in the effects of drugs and drug abuse liability. Biological factors, including ovarian hormones, may contribute to gender differences in drug abuse. Preclinical and some clinical research suggests that progesterone and its metabolites have activity at the GABA(A) receptor and may enhance the effect of GABAergic compounds (e.g., benzodiazepines). Because women are exposed to varying levels of progesterone from puberty until menopause, and appear more sensitive to the negative consequences of benzodiazepine use, it is important to understand the impact of progesterone on GABAergic drug effects. OBJECTIVES: The purpose of this experiment was to characterize the behavioral effects of progesterone, alone and in combination with the short-acting benzodiazepine, triazolam, to determine if progesterone potentiates the behavioral effects of triazolam... CONCLUSIONS: Progesterone potentiates the behavioral effects of benzodiazepines and may contribute to benzodiazepine use and abuse among women.
Dose effects of triazolam and scopolamine on metamemory. [2010.02]
The present study compared the acute dose effects of the benzodiazepine triazolam and the anticholinergic scopolamine on metamemory (knowledge and awareness of one's own memory) in a two-phase paradigm designed to assess effects on both monitoring and control components of metamemory in both semantic (general knowledge) and episodic memory (cued-recall) tasks...
Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial. [2009.05]
BACKGROUND: Incremental sublingual (SL) dosing of triazolam has emerged as a popular sedation technique. Nevertheless, few studies have evaluated the technique's safety or efficacy. Given its popularity, an easily administered rescue strategy is needed... CONCLUSIONS: Deep sedation from incremental SL dosing of triazolam is incompletely reversed by a single intraoral injection of flumazenil. The reversal did not persist. The authors discharged the patients from the dental clinic at 360 minutes. CLINICAL IMPLICATIONS: A single intraoral injection of flumazenil (0.2 mg) cannot immediately reverse oversedation with triazolam. A higher dose might be effective. Reversal for the purpose of discharging the patient early is neither appropriate nor safe.
Modulation of the discriminative stimulus effects of triazolam across the menstrual cycle phase in healthy pre-menopausal women. [2008.04.01]
Pre-clinical studies indicate that changes in progesterone levels across menstrual cycle phases modulate the behavioral effects of sedative drugs acting at GABA(A) receptor sites. In this study, seven healthy women learned to discriminate triazolam (0.25 mg/70 kg) from placebo... These results suggest that the discriminative stimulus effects of the positive GABA(A) modulator, triazolam, are sensitive to menstrual cycle phase in healthy adult women.
Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. [2006.11]
Although preclinical studies suggest that GHB has low likelihood for abuse, case reports indicate that GHB is abused. This study evaluated the relative abuse liability of GHB in 14 volunteers with histories of drug abuse... Although the likelihood for GHB to be abused is intermediate to triazolam and pentobarbital, the possibility of accidental overdose (ie greater sedation than intended) with GHB appears to be greater.
Reports of Suspected Halcion (Triazolam) Side Effects
Suicide Attempt (8),
Loss of Consciousness (6),
Toxicity TO Various Agents (6),
Blood Creatine Phosphokinase Increased (5),
Multiple Drug Overdose Intentional (5),
Drug Ineffective (4),
Intentional Overdose (4), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Halcion has an overall score of 3. The effectiveness score is 2 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Halcion review by 45 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || insomnia|
|Dosage & duration:|| || 5mg taken nightly for the period of 7 days|
|Other conditions:|| || weight loss|
|Other drugs taken:|| || none|
|Benefits:|| || Benefits were to treat insomnia.|
|Side effects:|| || None as long as directions were followed.|
|Comments:|| || Patient had severe insomnia. 45 years old, 5'7", 90 lbs. Was given 5 mg Halcion nightly to sleep and it had little effect. Patient was able to sleep 1-2 hours. She doubled dose and it still did not able her to sleep any longer.|
Page last updated: 2015-11-23